Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
Preprint
Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to the risk of drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.Keywords
All Related Versions
- Published version: Scientific Reports, 10 (1), 1.
This publication has 34 references indexed in Scilit:
- Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquineResearch in Social and Administrative Pharmacy, 2021
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart diseaseInternational Journal of Cardiology, 2020
- The epidemiology, diagnosis and treatment of COVID-19International Journal of Antimicrobial Agents, 2020
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?International Journal of Antimicrobial Agents, 2020
- Chloroquine for the 2019 novel coronavirus SARS-CoV-2International Journal of Antimicrobial Agents, 2020
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBioScience Trends, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the LiteratureDrug Safety, 2018
- Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseasesPharmacology Research & Perspectives, 2017